Sunshine Biopharma Inc. SBFM
life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries:
(i) Nora Pharma Inc. ("Nora Pharma"), a Canadian corporation, through which we currently have 71 generic prescription drugs
on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. ("Sunshine Canada"), a Canadian corporation which develops
and sells OTC supplements.
Last close
0.15
2026-10-23
Market cap
$581.6K
2026-06-30 share count
52-week range
0.13 - 23.20
Valuation FY2025 figures against the last close
P/S0.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228.4K | $71.4K | $21.1K | $0 | $0 | $0 |
| Cost of revenue | $24.1M | $24.2M | $15.8M | $2.6M | $117.8K | $25.8K | $11.1K | $0 | $0 | — |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110.6K | $45.6K | $10.1K | $0 | $0 | — |
| R&D | $604.3K | $933.9K | $1.9M | $811.9K | $672.2K | $1.7K | $15.2K | $12.8K | $0 | $32.8K |
| SG&A | $18.5M | $16.5M | $13.1M | $28.7M | $2.6M | $622.4K | $651.7K | $1.2M | $857.2K | $993.1K |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M | -$576.9K | -$641.6K | -$1.2M | -$857.2K | -$993.1K |
| Interest expense | $0 | $8.8K | $137.3K | $39.4K | $328.8K | $168.1K | $115.9K | $143.5K | $104.8K | $34.7K |
| Pre-tax income | -$6.0M | -$5.4M | -$4.1M | -$26.5M | -$12.4M | -$2.8M | — | — | — | — |
| Income tax | $21.6K | $234.9K | $395.2K | $233.3K | $0 | $0 | — | — | — | — |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M | -$2.8M | -$1.7M | -$2.2M | -$1.0M | -$3.5M |
| EPS, basic | -1.44 | -7.32 | -351.36 | -1.76 | -4.76 | -2.73 | -0.15 | -0.71 | -0.02 | -0.01 |
| EPS, diluted | — | -7.32 | -351.36 | -1.76 | -4.76 | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 4.2M | 701,749 | 12,825 | 15.2M | 2.6M | 1.0M | 10.9M | 3.0M | 43.6M | 424.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.1M | $9.7M | $16.3M | $21.8M | $2.0M | $989.9K | $40.5K | $110.5K | $107.5K | $57.5K |
| Receivables | $3.5M | $3.9M | $2.6M | $1.9M | $7.8K | $1.9K | $430 | $0 | $0 | — |
| Inventory | $13.5M | $11.3M | $5.7M | $3.3M | $105.7K | $23.8K | — | — | — | — |
| Total current assets | $26.9M | $26.0M | $24.9M | $27.3M | $2.2M | $1.0M | $65.7K | $1.1M | $117.2K | $58.5K |
| Property, plant and equipment | $557.4K | $546.1K | $365.9K | $394.2K | $7.1K | $19.5K | $32.5K | $45.1K | $60.0K | $5.9K |
| Goodwill | — | $0 | $0 | $0 | $0 | — | $665.7K | $665.7K | $0 | — |
| Other intangibles | $1.9M | $3.0M | $1.4M | $776.9K | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M | $1.0M | $98.1K | $1.1M | $257.5K | $64.4K |
| Accounts payable | $5.7M | $5.5M | $2.6M | $2.8M | $42.9K | $62.9K | $96.9K | $115.8K | $19.3K | $28.1K |
| Total current liabilities | $6.4M | $6.3M | $5.6M | $6.9M | $91.2K | $1.1M | $833.5K | $912.5K | $751.1K | $274.1K |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M | $2.0M | $833.5K | $1.2M | $830.8K | $274.1K |
| Retained earnings | -$75.0M | -$69.0M | -$63.9M | -$59.4M | -$32.7M | -$20.2M | -$17.4M | -$15.8M | -$13.6M | -$12.6M |
| Total equity | $23.0M | $23.5M | $21.2M | $21.6M | $211.7K | -$954.8K | -$735.4K | -$55.8K | -$573.4K | -$209.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M | -$657.3K | -$495.8K | -$512.8K | -$543.5K | -$314.2K |
| Depreciation and amortisation | $332.1K | $223.5K | $149.1K | $20.6K | $12.7K | $14.1K | — | — | — | $1.8K |
| Stock-based compensation | — | — | — | — | — | $271.9K | $277.3K | $755.2K | $520.3K | $499.4K |
| Capital expenditure | $174.5K | $1.7M | $82.3K | $194.0K | $0 | $1.2K | $860 | $18.9K | $3.7K | $3.4K |
| Investing cash flow | -$836.3K | -$2.0M | -$656.1K | -$14.6M | $0 | -$1.2K | -$15.3K | -$13.9K | -$84.0K | -$3.4K |
| Financing cash flow | $4.7M | $8.9M | $3.4M | $39.5M | $2.9M | $1.6M | $442.3K | $527.6K | $670.7K | $324.6K |
| Buybacks | $0 | $3.1M | $541.1K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-002644.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $21.1K | $71.4K | $228.4K | $4.3M | $24.1M | $34.9M | $36.3M |
| Gross profit | — | $0 | $0 | $10.1K | $45.6K | $110.6K | $1.7M | $8.3M | $10.7M | $12.3M |
| Net income | -$3.5M | -$1.0M | -$2.2M | -$1.7M | -$2.8M | -$12.4M | -$26.7M | -$4.5M | -$5.1M | -$6.0M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Other event Item 8.01
- Shareholder vote Item 5.07
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |